Abstract
Summary
LPI (LP Information)' newest research report, the “Nocturnal Polyuria Treatment Industry Forecast” looks at past sales and reviews total world Nocturnal Polyuria Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Nocturnal Polyuria Treatment sales for 2023 through 2029. With Nocturnal Polyuria Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nocturnal Polyuria Treatment industry.
This Insight Report provides a comprehensive analysis of the global Nocturnal Polyuria Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nocturnal Polyuria Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nocturnal Polyuria Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nocturnal Polyuria Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nocturnal Polyuria Treatment.
The global Nocturnal Polyuria Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nocturnal Polyuria Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nocturnal Polyuria Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nocturnal Polyuria Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nocturnal Polyuria Treatment players cover Allergan, Ferring Holding, Teva Pharmaceutical Industries, Urigen Pharmaceuticals, Vantia Therapeutics and Astellas Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nocturnal Polyuria Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antispasmodic
Desmopressin
Anticholinergic drugs
Other
Segmentation by application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Ferring Holding
Teva Pharmaceutical Industries
Urigen Pharmaceuticals
Vantia Therapeutics
Astellas Pharma
This Insight Report provides a comprehensive analysis of the global Nocturnal Polyuria Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Nocturnal Polyuria Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Nocturnal Polyuria Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nocturnal Polyuria Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nocturnal Polyuria Treatment.
The global Nocturnal Polyuria Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Nocturnal Polyuria Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Nocturnal Polyuria Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Nocturnal Polyuria Treatment is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Nocturnal Polyuria Treatment players cover Allergan, Ferring Holding, Teva Pharmaceutical Industries, Urigen Pharmaceuticals, Vantia Therapeutics and Astellas Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Nocturnal Polyuria Treatment market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Antispasmodic
Desmopressin
Anticholinergic drugs
Other
Segmentation by application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Allergan
Ferring Holding
Teva Pharmaceutical Industries
Urigen Pharmaceuticals
Vantia Therapeutics
Astellas Pharma
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nocturnal Polyuria Treatment Market Size 2018-2029
2.1.2 Nocturnal Polyuria Treatment Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Nocturnal Polyuria Treatment Segment by Type
2.2.1 Antispasmodic
2.2.2 Desmopressin
2.2.3 Anticholinergic drugs
2.2.4 Other
2.3 Nocturnal Polyuria Treatment Market Size by Type
2.3.1 Nocturnal Polyuria Treatment Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Nocturnal Polyuria Treatment Market Size Market Share by Type (2018-2023)
2.4 Nocturnal Polyuria Treatment Segment by Application
2.4.1 Hospital Pharmacy
2.4.2 Online Pharmacy
2.4.3 Retail Pharmacy
2.4.4 Other
2.5 Nocturnal Polyuria Treatment Market Size by Application
2.5.1 Nocturnal Polyuria Treatment Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Nocturnal Polyuria Treatment Market Size Market Share by Application (2018-2023)
3 Nocturnal Polyuria Treatment Market Size by Player
3.1 Nocturnal Polyuria Treatment Market Size Market Share by Players
3.1.1 Global Nocturnal Polyuria Treatment Revenue by Players (2018-2023)
3.1.2 Global Nocturnal Polyuria Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Nocturnal Polyuria Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Nocturnal Polyuria Treatment by Regions
4.1 Nocturnal Polyuria Treatment Market Size by Regions (2018-2023)
4.2 Americas Nocturnal Polyuria Treatment Market Size Growth (2018-2023)
4.3 APAC Nocturnal Polyuria Treatment Market Size Growth (2018-2023)
4.4 Europe Nocturnal Polyuria Treatment Market Size Growth (2018-2023)
4.5 Middle East & Africa Nocturnal Polyuria Treatment Market Size Growth (2018-2023)
5 Americas
5.1 Americas Nocturnal Polyuria Treatment Market Size by Country (2018-2023)
5.2 Americas Nocturnal Polyuria Treatment Market Size by Type (2018-2023)
5.3 Americas Nocturnal Polyuria Treatment Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nocturnal Polyuria Treatment Market Size by Region (2018-2023)
6.2 APAC Nocturnal Polyuria Treatment Market Size by Type (2018-2023)
6.3 APAC Nocturnal Polyuria Treatment Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Nocturnal Polyuria Treatment by Country (2018-2023)
7.2 Europe Nocturnal Polyuria Treatment Market Size by Type (2018-2023)
7.3 Europe Nocturnal Polyuria Treatment Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nocturnal Polyuria Treatment by Region (2018-2023)
8.2 Middle East & Africa Nocturnal Polyuria Treatment Market Size by Type (2018-2023)
8.3 Middle East & Africa Nocturnal Polyuria Treatment Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Nocturnal Polyuria Treatment Market Forecast
10.1 Global Nocturnal Polyuria Treatment Forecast by Regions (2024-2029)
10.1.1 Global Nocturnal Polyuria Treatment Forecast by Regions (2024-2029)
10.1.2 Americas Nocturnal Polyuria Treatment Forecast
10.1.3 APAC Nocturnal Polyuria Treatment Forecast
10.1.4 Europe Nocturnal Polyuria Treatment Forecast
10.1.5 Middle East & Africa Nocturnal Polyuria Treatment Forecast
10.2 Americas Nocturnal Polyuria Treatment Forecast by Country (2024-2029)
10.2.1 United States Nocturnal Polyuria Treatment Market Forecast
10.2.2 Canada Nocturnal Polyuria Treatment Market Forecast
10.2.3 Mexico Nocturnal Polyuria Treatment Market Forecast
10.2.4 Brazil Nocturnal Polyuria Treatment Market Forecast
10.3 APAC Nocturnal Polyuria Treatment Forecast by Region (2024-2029)
10.3.1 China Nocturnal Polyuria Treatment Market Forecast
10.3.2 Japan Nocturnal Polyuria Treatment Market Forecast
10.3.3 Korea Nocturnal Polyuria Treatment Market Forecast
10.3.4 Southeast Asia Nocturnal Polyuria Treatment Market Forecast
10.3.5 India Nocturnal Polyuria Treatment Market Forecast
10.3.6 Australia Nocturnal Polyuria Treatment Market Forecast
10.4 Europe Nocturnal Polyuria Treatment Forecast by Country (2024-2029)
10.4.1 Germany Nocturnal Polyuria Treatment Market Forecast
10.4.2 France Nocturnal Polyuria Treatment Market Forecast
10.4.3 UK Nocturnal Polyuria Treatment Market Forecast
10.4.4 Italy Nocturnal Polyuria Treatment Market Forecast
10.4.5 Russia Nocturnal Polyuria Treatment Market Forecast
10.5 Middle East & Africa Nocturnal Polyuria Treatment Forecast by Region (2024-2029)
10.5.1 Egypt Nocturnal Polyuria Treatment Market Forecast
10.5.2 South Africa Nocturnal Polyuria Treatment Market Forecast
10.5.3 Israel Nocturnal Polyuria Treatment Market Forecast
10.5.4 Turkey Nocturnal Polyuria Treatment Market Forecast
10.5.5 GCC Countries Nocturnal Polyuria Treatment Market Forecast
10.6 Global Nocturnal Polyuria Treatment Forecast by Type (2024-2029)
10.7 Global Nocturnal Polyuria Treatment Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Allergan
11.1.1 Allergan Company Information
11.1.2 Allergan Nocturnal Polyuria Treatment Product Offered
11.1.3 Allergan Nocturnal Polyuria Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Allergan Main Business Overview
11.1.5 Allergan Latest Developments
11.2 Ferring Holding
11.2.1 Ferring Holding Company Information
11.2.2 Ferring Holding Nocturnal Polyuria Treatment Product Offered
11.2.3 Ferring Holding Nocturnal Polyuria Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Ferring Holding Main Business Overview
11.2.5 Ferring Holding Latest Developments
11.3 Teva Pharmaceutical Industries
11.3.1 Teva Pharmaceutical Industries Company Information
11.3.2 Teva Pharmaceutical Industries Nocturnal Polyuria Treatment Product Offered
11.3.3 Teva Pharmaceutical Industries Nocturnal Polyuria Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Teva Pharmaceutical Industries Main Business Overview
11.3.5 Teva Pharmaceutical Industries Latest Developments
11.4 Urigen Pharmaceuticals
11.4.1 Urigen Pharmaceuticals Company Information
11.4.2 Urigen Pharmaceuticals Nocturnal Polyuria Treatment Product Offered
11.4.3 Urigen Pharmaceuticals Nocturnal Polyuria Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Urigen Pharmaceuticals Main Business Overview
11.4.5 Urigen Pharmaceuticals Latest Developments
11.5 Vantia Therapeutics
11.5.1 Vantia Therapeutics Company Information
11.5.2 Vantia Therapeutics Nocturnal Polyuria Treatment Product Offered
11.5.3 Vantia Therapeutics Nocturnal Polyuria Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Vantia Therapeutics Main Business Overview
11.5.5 Vantia Therapeutics Latest Developments
11.6 Astellas Pharma
11.6.1 Astellas Pharma Company Information
11.6.2 Astellas Pharma Nocturnal Polyuria Treatment Product Offered
11.6.3 Astellas Pharma Nocturnal Polyuria Treatment Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Astellas Pharma Main Business Overview
11.6.5 Astellas Pharma Latest Developments
12 Research Findings and Conclusion